Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to -$71,000.

  • Xeris Biopharma Holdings' Cash from Investing Activities fell 100.72% to -$71,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 0.84%. This contributed to the annual value of $4.9 million for FY2024, which is 181.33% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Cash from Investing Activities stood at -$71,000 for Q3 2025, which was up 74.55% from -$279,000 recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Cash from Investing Activities peaked at $36.6 million during Q4 2021, and registered a low of -$44.0 million during Q1 2023.
  • Its 3-year average for Cash from Investing Activities is -$134,909, with a median of $4.6 million in 2024.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Cash from Investing Activities skyrocketed by 404.92% in 2021 and then plummeted by 754.84% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Cash from Investing Activities (Quarterly) stood at $36.6 million in 2021, then tumbled by 74.95% to $9.2 million in 2022, then surged by 62.17% to $14.9 million in 2023, then crashed by 32.63% to $10.0 million in 2024, then crashed by 100.72% to -$71,000 in 2025.
  • Its Cash from Investing Activities was -$71,000 in Q3 2025, compared to -$279,000 in Q2 2025 and -$13,000 in Q1 2025.